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Abstract
Background: Adipose-derived mesenchymal stem cells (ASCs) are a promising cell therapy to treat inflammatory
and immune-mediated diseases. Development of appropriate pre-clinical animal models is critical to determine
safety and attain early efficacy data for the most promising therapeutic candidates. Naturally occurring diseases
in cats already serve as valuable models to inform human clinical trials in oncologic, cardiovascular, and genetic
diseases. The objective of this study was to complete a comprehensive side-by-side comparison of human and
feline ASCs, with an emphasis on their immunomodulatory capacity and transcriptome.
Methods: Human and feline ASCs were evaluated for phenotype, immunomodulatory profile, and transcriptome.
Additionally, transwells were used to determine the role of cell-cell contact in ASC-mediated inhibition of
lymphocyte proliferation in both humans and cats.
Results: Similar to human ASCs, feline ASCs were highly proliferative at low passages and fit the minimal criteria
of multipotent stem cells including a compatible surface protein phenotype, osteogenic capacity, and normal
karyotype. Like ASCs from all species, feline ASCs inhibited mitogen-activated lymphocyte proliferation in vitro,
with or without direct ASC-lymphocyte contact. Feline ASCs mimic human ASCs in their mediator secretion pattern,
including prostaglandin E2, indoleamine 2,3 dioxygenase, transforming growth factor beta, and interleukin-6, all
augmented by interferon gamma secretion by lymphocytes. The transcriptome of three unactivated feline ASC
lines were highly similar. Functional analysis of the most highly expressed genes highlighted processes including:
1) the regulation of apoptosis; 2) cell adhesion; 3) response to oxidative stress; and 4) regulation of cell
differentiation. Finally, feline ASCs had a similar gene expression profile to noninduced human ASCs.
Conclusions: Findings suggest that feline ASCs modulate lymphocyte proliferation using soluble mediators that
mirror the human ASC secretion pattern. Uninduced feline ASCs have similar gene expression profiles to uninduced
human ASCs, as revealed by transcriptome analysis. These data will help inform clinical trials using cats with
naturally occurring diseases as surrogate models for human clinical trials in the regenerative medicine arena.
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Background
Mesenchymal (multipotent) stem cells (MSCs) are pro-
liferative, plastic adherent, fibroblast-like stromal cells
that can be isolated from many tissue types [1]. Adipose
tissue is an important tissue source for MSC expansion
(ASCs) [2]. Fat collection is relatively noninvasive, the
frequency of MSCs in fat is about 10-fold higher than
in bone marrow, and fat is more readily available in small
animals, older animals, and people. In comparative stud-
ies, ASCs appear to be highly enriched in immune-related
genes and may have advantages in terms of proliferation,
stability, and immunomodulatory ability, perhaps as a re-
sult of their retaining the metabolic and inflammatory
modulating transcriptome native to its tissue [3–7].
Immunomodulation by MSCs represents a novel thera-
peutic option for various inflammatory and immune-
mediated diseases [2, 8, 9]. MSCs modulate cell activation,
differentiation, and secretion of almost all cells of the
innate and humoral immune systems. MSCs inhibit T-cell
proliferation with an associated decrease in tumor ne-
crosis factor (TNF)α secretion in humans, rodents, and
veterinary species including horses and dogs [8–10].
Human, equine, and canine ASCs secrete soluble media-
tors that are known to be immunomodulatory, including
prostaglandin E2 (PGE2), indoleamine 2,3 dioxygenase
(IDO), interleukin (IL)-6, IL-8, transforming growth factor
(TGF)β, and vascular endothelial growth factor (VEGF)
[6, 7, 11–14]. Human MSCs and ASCs also regulate T-cell
and B-cell function via direct cell-cell interaction [15–17].
The increased recognition of the role of MSCs in immu-
nomodulation, combined with successes in phase I–III
clinical trials in humans using stem cell therapy for in-
flammatory and immune-mediated diseases, has resulted
in recommendations that immune functional assays be de-
veloped as potency-release criteria for advanced-phase
clinical trials [18].
Naturally occurring diseases in companion animals
are increasingly recognized for the important role they
play in discovery about human diseases and transla-
tional medicine [19]. These diseases in companion
animals may better reflect the complex genetic, envir-
onmental, and physiological variations present in
human diseases compared to induced diseases in la-
boratory animals [20]. Clinical trials in academic vet-
erinary medicine mirror that of human healthcare
systems, and animal owners are eager to enroll in
these trials [20]. The selection of appropriate large
animal models for preclinical testing in human stem
cell trials should rely on solid comparative studies, as
MSCs from rodents may or may not recapitulate the
immunomodulatory profile of human MSCs. For ex-
ample, there are important differences between human
and murine MSC secretion profiles that may dictate how
predictive mouse models are for studies that focus on
MSCs and innate immune cells, CD8+ T cells, and
mechanism-of-action studies [9, 21–23].
Companion animals can serve as relevant, preclinical,
surrogate, translational models for MSC therapy and
contribute directly to investigational new drug applica-
tions for human clinical trials. Cats with naturally
occurring diseases analogous to human conditions can
provide insight into feasibility, safety, and biologic activ-
ity of novel stem cell therapies. The development of
appropriate and relevant large animal models will: 1)
reduce the work needed when translating pre-clinical
data to human trials; and 2) assist in choosing human
trials to pursue. Naturally occurring diseases in cats can
help determine the ideal route of cell administration, cell
dose, the number of cell doses, and efficacy readouts to
optimize the potential for successful human clinical
trials. Cats develop a variety of spontaneous inflamma-
tory and immune-mediated diseases, and stem cell ther-
apy trials are already underway for chronic oral mucosa
inflammation [24], asthma [25], and chronic enteropathy
[26]. For example, feline chronic gingivostomatitis has a
similar T-cell activation phenotype to the human oral in-
flammatory diseases oral lichen planus, apthous stoma-
titis, and pemphigus vulgaris [27, 28]. Cats also serve as
valuable models for noninflammatory diseases, including
chronic renal failure [29, 30].
The objectives of this work were to delineate a com-
prehensive immunomodulatory profile of feline ASCs
and to perform a direct side-by-side comparison of
feline and human ASCs as a first step in determining
how ASCs from this relevant large animal species com-
pare to human ASCs. We found that cat ASCs largely
mimic human ASCs in basic phenotype, early proliferative
ability, transcriptome, secretion profile (notably IDO and




Human adipose tissue was obtained as discarded material
from female patients undergoing a breast reduction pro-
cedure in compliance with an approved protocol (n = 5;
University of California, Davis (UCD) Institutional
Research Board, protocol number 258314-8). For all hu-
man tissues collected, informed patient consent forms
were obtained. Subcutaneous feline adipose tissue was
surgically obtained from specific pathogen-free (SPF) cats
(n = 3) and from client-owned cats (n = 3) undergoing
routine surgery. Fat collection was conducted according
to a protocol approved by the Institutional Animal Care
and Use Committee, and the Clinical Trials Review Board,
UCD (protocol number 18422). All owners of client-
owned cats signed an informed consent form. All cats
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were free of feline immune deficiency virus and feline
leukemia virus infection.
Human ASC isolation and expansion
Adipose tissue (~20 g) was mixed with 10 mL phosphate-
buffered saline (PBS) and homogenized (gentleMACS dis-
sociator; Miltenyi Biotec, San Diego, CA, USA). Samples
were centrifuged at 1500 rpm for 5 min and the cell/tissue
pellet was incubated with 10 mL animal origin-free colla-
genase (CLSAFA, 267 U/mL; Worthington Biochemical,
Lakewood, NJ, USA) for 30 mins with gentle agitation at
37 °C. Samples were centrifuged at 2000 rpm for 7 min
and cell pellets were resuspended and plated at 1000
cells/cm2 in plastic culture flasks using standard culture
medium (minimum essential medium (MEM)α; GE
Healthcare Life Sciences HyClone Laboratories, Logan,
UT, USA) supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Flowery Branch, GA, USA),
1% L-glutamine, and 1% penicillin/streptomycin (Ther-
moFisher Scientific, Gibco, Pittsburgh, PA, USA). After
2 days, nonadherent cells were removed by washing
twice with PBS. MSCs from passages 3–5 were used for
experimentation.
Feline ASC isolation and expansion
ASCs were isolated from fat and cultured as previously
described [24]. ASCs from passages 3–5 were used for
experimentation.
ASC morphology and size
Adherent feline and human ASCs were imaged on a
phase-contrast microscope using bright field. To quantify
cell sizes, images were taken of five random areas of two
human and two feline ASC lines grown in T225 flasks.
Twenty cells from each image were measured using
ImageJ software.
Comparison of cell size in suspension of human (n = 2)
and feline (n = 2) ASCs was assessed by flow cytometry.
Human ASCs were labeled using CD105 conjugated with
APC (BD Biosciences, Pharmingen, San Jose, CA, USA)
and feline ASCs were labeled using CD90 conjugated with
PE (Leukocyte Antigen Biology Laboratory, UCD, clone
CA1.4G8) as previously described [24, 31]. Labeled
human and feline lines were mixed 1:1 and read on a flow
cytometer (Cytomics FC500; Beckman Coulter, Brea, CA,
USA). Cell size of fluorochrome-labeled human and feline
cells was determined by forward and side scatter.
Karyotype
Feline (n = 2, passage 5) and human (n = 2, passage 4)
ASCs were karyotyped as previously described [32]. ASCs
were plated in a six-well plate, treated with colcemid
(ThermoFisher Scientific) to arrest the mitotic cells in
metaphase, lifted and prepared with serial washes and
fixations for staining and microscopic analysis. Analysis
included scanning all slides, counting a minimum of 20
metaphases, analysis of a minimum of seven metaphases,
and karyotyping a minimum of two metaphases.
ASC surface phenotype
Human and feline ASCs (n = 5 each) were incubated for
45 min with fluorophore-conjugated antibodies includ-
ing CD44, CD45 (human ASCs), CD18 (feline ASCs),
CD90, CD105, and MHCII as previously described [24,
31]. All human antibodies were purchased from BD
Biosciences and feline antibodies were purchased from
the Leukocyte Antigen Biology Laboratory, UCD, unless
otherwise indicated (MHC II (clone 42.3), CD18 (clone
FE3.9 F2), CD90 (clone CA1.4G8), CD44 (clone IM7;
BioLegend, San Diego, CA, USA), and CD105 (SN6;
eBioscience, SanDiego, CA, USA). Mouse IgG-APC
(MCA928; AbD Serotec, Kidlington, Oxford, UK) was
used as an isotype control. All samples were run on a
flow cytometer (Cytomics FC500). Flow cytometry data
were analyzed using FlowJo flow cytometry software
(Tree Star, Ashland, OR, USA).
Osteogenesis
Osteogenic assays were performed as previously described
[33, 34]. In brief, 10,000 ASCs/cm2 were cultured for
14 days with media changes every 3 days (n = 2 human
ASCs and n = 2 feline ASCs). Osteogenic medium con-
sisted of standard culture medium supplemented with
0.2 mM ascorbic acid (Sigma-Aldrich, St. Louis, MO,
USA), 0.1 μM dexamethasone (Sigma-Aldrich), and
20 mM β-glycerolphosphate. Cells were fixed with 10%
vol/vol formalin solution for 15 min, washed once with
PBS, and stained for 20 min with 1% wt/vol Alizarin Red
S (ARS, Ricca Chemical Company, Arlington, TX, USA)
with gentle shaking to stain for precipitated calcium
(Sigma-Aldrich). Samples were then photographed.
ASC proliferation
ASCs (n = 4 human, n = 5 feline) were plated into two T25
flasks at 5000 cells/cm2. At each passage, ASC viability was
determined (trypan blue exclusion dye; ThermoFisher
Scientific) and ASCs were enumerated (by hemocytometer).
ASCs were passaged at 70–80% confluence. In order to
normalize differences in when cells were passaged, popula-
tion doubling times were calculated as previously described
[35]. Cultures were terminated at passage 6.
Lymphocyte suppression assay (LSA)
LSAs were run, with and without a transwell, to com-
pare the ability of feline and human ASCs to inhibit
activated T-cell proliferation and to determine if T cell-
ASC contact is necessary for inhibition of lymphocyte
proliferation (n = 5 feline and n = 5 human lines). Our
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goal was to maximally stimulate human and feline T-cell
proliferation using mitogens. Previous work in our labora-
tory in horses [14], dogs, and cats (unpublished data)
demonstrated that allogenic peripheral blood mono-
nuclear cells (PBMCs) only weakly and variably stimulate
T-cell proliferation. Our pilot data demonstrated, in
agreement with others, that concanavalin A (ConA) is the
best and most potent mitogen for mature, circulating,
post-thymic cells in cats (unpublished data and [36–38])
whereas leucoagglutinin (PHA) is the best T-cell mitogen
for human T lymphocytes [39, 40].
Feline PBMC isolation and LSAs were carried out as
previously described [14, 24]. In brief, PBMCs were iso-
lated from whole blood using gradient centrifugation
and were co-incubated with irradiated ASCs in culture
wells at a 1:5 (PBMC:ASC) ratio and activated with
5 mg/mL ConA (Sigma-Aldrich). Cells were co-cultured
for 4 days. Control wells included PBMCs alone, ASCs
alone, ConA-stimulated PBMCs, and PBMCs mixed with
ASCs without ConA stimulation. To determine the role
of contact, cells were plated in transwell dishes (Corning
0.4 μM polycarbonate membrane 24-well plate; Corning,
NY, USA) with PBMCs in the bottom and ASCs in the
insert. To determine IDO activity, the experiment was
run as described; however, media were supplemented
with L-tryptophan (Sigma-Aldrich) to a final concentra-
tion of 600 μM.
For human LSAs, PBMCs were isolated using Ficoll-
Paque (GE Healthcare) according to the manufacturer’s
instructions and MSC-PBMC co-incubation, with and
without transwells, was performed as previously described
for feline LSAs except the medium used was αMEM
(GE Healthcare Life Sciences) with 16% FBS (Atlanta
Biologicals), 1% penicillin/streptomycin (ThermoFisher
Scientific), and 1% Glutamax (ThermoFisher Scientific),
and the PBMCs were stimulated with PHA (Sigma-
Aldrich; 2.5 μg/ml) [39, 40].
Human and feline PBMC proliferation was measured
via 5-bromo-29-deoxyuridine (BrdU) incorporation (BrdU
Flow Kit; BD Biosciences) and analyzed on a flow cyt-
ometer (Cytomics FC500). Flow cytometry data were ana-
lyzed using FlowJo flow cytometry software (Tree Star).
Mediator secretion (ELISA)
Feline and human PGE2, TGFβ1, VEGF, interferon (IFN)γ,
TNFα, IL-6, IL-8, and IL-10 were measured in LSA super-
natants in duplicate using enzyme-linked immunosorbent
assay (ELISA) kits following the manufacturer’s instruc-
tions. Feline analytes were measured with feline-specific
kits (IFNγ, TNFα, IL-6, IL-8, and IL-10: Duosets; R&D
Systems, Minneapolis, MN, USA) or feline-validated kits
(TGFβ1: multispecies TGF-β1 (ThermoFisher Scientific)
[41]; VEGF: human QuantiKine Kit (R&D) [42, 43];
and PGE2: competitive ELISA (Enzo Life Sciences,
Farmingdale, NY, USA) [44, 45]). Human TGFβ1, VEGF,
IFNγ, TNFα (QuantiKine), PGE2, (competitive ELISA kit),
IL-6, IL-8, and IL-10 (DuoSets) were all purchased
from R&D. All ELISA samples were read on a Synergy
HTMulti-Mode microplate reader with Gen5 software
(Biotek, Winooski, VT, USA).
IDO assay
IDO catalyzes the conversion of tryptophan to N-formyl
kynurenine, which is then catabolized to kynurenine.
Kynurenine levels are directly proportional to IDO activ-
ity. Two volumes of LSA media (that had been supple-
mented with tryptophan) were treated with 1 volume of
30% trichloroacetic acid (Sigma-Adrich) and centrifuged.
Equal parts of trichloroacetic acid-treated supernatant
and Ehrlich’s reagent (1% p-dimethylaminobenzaldehyde
in glacial acetic acid; Sigma-Aldrich) were mixed and
read at 490 nm on a microplate reader (Synergy HT
Multi-Mode Gen5 software) [14].
RNA isolation
Total RNA was isolated from three primary feline ASC
cultures using the RNeasy Mini Kit (Qiagen, Inc., Valencia,
CA, USA). RNA quantity and quality were assessed on a
NanoDrop spectrophotometer (Thermo Scientific) and
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), respectively.
RNA-Seq library preparation and next-generation
sequencing (NGS)
Whole transcriptome profiling was performed using a
directional, strand-specific mRNA-Seq approach for
three feline ASC lines. Briefly, total RNA samples were
submitted to the UC Davis Comprehensive Cancer
Center’s Genomics Shared Resource (GSR), and indexed
RNA-Seq libraries were prepared from 200 ng total RNA
using the KAPA Stranded mRNA-Seq Kit (Kapa Biosys-
tems, Inc., Wilmington, MA, USA) according to the man-
ufacturer’s standard protocol. Poly-adenylated mRNA was
purified from total RNA and ribosomal RNA removed by
binding to oligo (dT) beads, which was followed by RNA
fragmentation by incubation at 94 °C in the presence of
magnesium. Double-stranded cDNA was then generated
by random-primed first-strand synthesis and subsequent
second-strand synthesis in the presence of dUTP for
strand marking. The double-stranded cDNA was then 3’-
A tailed and indexed, Illumina-compatible adapters were
ligated. The libraries were then enriched by high-fidelity
PCR amplification (15 cycles) with KAPA HiFi HotStart
DNA Polymerase and adapter-specific primers. Subse-
quently, libraries were combined for multiplex sequencing
on an Illumina HiSeq 4000 System (100-bp, paired-end;
~30 million reads/sample) [46].
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Next generation sequencing data analysis
Image processing, base calling, quality scoring (Phred),
and sample demultiplexing were executed by HiSeq
Control Software with Real Time Analysis (HCS v3.3.41/
RTA 2.5.2) and bcl2fastq Conversion Software (Illumina;
San Diego, CA, USA). FASTQ-formatted sequence data
were analyzed using a standard HISAT (hierarchical
indexing for spliced alignment of transcripts)-Cufflinks
workflow. RNA-Seq sequence reads (FASTQ format)
were aligned to the reference cat genome assembly
(Nov. 2014, ICGSC Felis Catus 8.0) using HISAT soft-
ware [47]. Gene- and transcript-level expression were
comprehensively quantified with Cufflinks software [48],
which performed: 1) transcript assembly; 2) identifica-
tion of splice variants; 3) quantification of expression as
FPKM (fragments per kilobase of transcript per million
mapped reads) values; and 4) normalization. Normalized
FPKM values (Cuffnorm output) were utilized for down-
stream analysis steps. Statistical analyses and hierarchical
clustering of the data were performed with GeneSpring
GX software (Agilent Technologies, Inc.), and gene-
annotation enrichment analysis performed with tools
available from the Database for Annotation, Visualization
and Integrated Discovery (DAVID v6.7) [49, 50].
Meta-analysis of the feline ASC expression data was
performed with RNA-Seq data for human ASCs (NCBI
GEO Accession GSE37521) [51]. For this, gene expres-
sion values from both datasets (feline ASCs: FPKM;
human ASCs: RPKM (Reads Per Kilobase of transcript
per Million mapped reads)) were separately normalized
(quantile), joined on similar Gene IDs, and then
baseline-transformed. Values for replicate samples were
averaged and, subsequently, hierarchical clustering
(similarity measure: Euclidean; linkage rule: centroid)
was performed on the genes exhibiting variance across
the human ASC cell types (≥2-fold change relative to
undifferentiated ASCs).
Statistical analyses
For all cell-based assays, normal distribution of the data
was tested using the Kolmogorov and Smirnov test. For
normally distributed data, a one sample Student’s t test
(normalized data; lymphocyte proliferation) or paired t
test (non-normalized data) or analysis of variance
(ANOVA; >2 comparisons) was used. For feline non-
normally distributed data, a Mann–Whitney-Wilcoxon
test was used to determine differences in protein secre-
tion data. Human data were analyzed using Wilcoxon
matched pairs test. Human inflammatory mediators
were normalized to paired lymphocyte donors before
analysis was performed. Commercially available statis-
tical software was used for all statistical analyses
(GraphPad InStat version 3.06 for Windows; GraphPad,
La Jolla, CA, USA). Results are presented as mean and
standard error. A P value of <0.05 was considered sta-
tistically significant.
Results
Human and feline ASCs are morphologically and
phenotypically similar
The ASCs derived from feline and human adipose tissue
had typical spindle-shaped, adherent morphology (Fig. 1a
and b). However, human ASCs were significantly larger,
both when adhered to plastic and when in suspension,
than feline ASCs (adherent cells, p < 0.001, Fig. 1c; sus-
pended ASCs, Fig. 1d). Both feline and human ASCs had
a normal metaphase spread and karyotype (Additional file
1: Figure S1). The surface protein expression on feline and
human ASCs was compared using markers that define
MSCs [1]. Both feline and human ASCs were strongly
positive for CD44, CD90, and CD105, and were negative
for leukocyte markers (CD18 (feline) and CD45 (human)),
and MHCII (Fig. 1e and f) [31, 52, 53]. Both feline and
human ASCs were capable of osteogenic differentiation
(Fig. 1g and h). Others have established the full trilineage
differentiation capacity of feline ASCs, including chondro-
genic and adipogenic differentiation [52, 54–57]. Together,
these data suggest that feline ASCs are karyotypically
normal, meet the minimal criteria of multipotent stem
cells and are smaller but otherwise morphologically and
phenotypically identical to human ASCs.
Human and feline ASCs are highly proliferative and
inhibit allogeneic mitogen activated T-cell proliferation
Human and feline ASCs readily proliferated in culture
with comparable doubling times from passages 3–6
(clinically relevant passage numbers; Fig. 2a). Previous
data from our laboratory and others has demonstrated a
significant slowing of feline ASC proliferation after
passage 5 [31, 52]. Human and feline ASCs significantly
reduced activated T-cell proliferation (P < 0.004 all condi-
tions compared to positive control; Fig. 2b and c). This
inhibition occurred with or without ASC-T cell contact.
However, human ASCs, when in direct contact with
activated T cells, more potently reduced activated T-cell
proliferation as compared to human ASCs plated in trans-
wells (P = 0.03; Fig. 2c). These findings suggest that feline
ASCs, like other species, are potent modulators of acti-
vated T-cell proliferation and that this modulation is
largely mediated by secreted factors. Interestingly, human
ASCs also markedly decrease activated T-cell prolifera-
tion, but this regulation is stronger when ASCs are in
direct contact with T cells.
Activated human and feline ASCS secrete high
concentrations of immunomodulatory mediators
ASCs function in large part via the secretion of mediators
that regulate cells of the cellular and humoral immune
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system. We measured a number of mediators implicated
in the immunomodulatory function of ASCs in parallel
feline and human assays, with and without activation, and
with or without cell-cell contact, to define feline ASCs
and dissect out similarities and dissimilarities between cat
and human ASCs. ASCs of both species variably secrete
very low concentrations of IDO, PGE2, IL-6, and VEGF at
baseline in culture, or in the context of allogeneic PBMCs;
however, ASCs in the context of mitogen-activated T cells
secrete significantly higher concentrations of immuno-
modulatory mediators. Activated feline ASCs secreted
high concentrations of IDO (Fig. 3a), similar to canine and
human MSCs (Fig. 3b) but unlike murine MSCs [21].
Activated feline ASCs also secrete high concentrations of
PGE2 (Fig. 3c) that, unlike human ASCs (Fig. 3d), is sig-
nificantly augmented by ASC-T cell contact. Activated
feline and human ASCs secrete high concentrations of IL-
6 (Fig. 3e and f) and VEGF (Fig. 3g and h), with or without
MSC-T cell contact. Human ASC secretion of VEGF was
not enhanced by T-cell activation (Fig. 3h).
We measured two mediators, IL-8 and TGFβ, that
are potentially secreted by both activated PBMCs and
ASCs (Fig. 4). For both feline and human cells, more
IL-8 is present in activated ASC-PBMC co-cultures
than is present in cultures with ASCs alone (Fig. 4a and b;
P = 0.08) regardless of cell-cell contact. Cell-cell contact
significantly increased IL-8 secretion for human cultures
(P < 0.05) but not for feline cultures (P = 0.12). Feline
TGFβ secretion mimicked our findings for human ASCs.
Regardless of species, TGFβ was secreted by activated
PBMCs, by ASCs at baseline, and in the context of ASC-
PBMC co-incubation, with or without activation and with
Fig. 1 Human and feline ASCs possess typical MSC characteristics. Feline (a) and human (b) ASCs adhere to plastic and have a spindle, fibroblast
morphology in culture. However, human ASCs are significantly larger than feline ASCs when adherent (c) and in suspension (d). Feline (e) and
human (f) ASCs both have positive surface expression of CD44, CD90, and CD105, and are negative for surface expression of CD45 (pan leukocyte,
human) or CD18 (pan leukocyte, feline) and MHC II. Both feline (g) and human (h) ASCs undergo osteogenic differentiation. Cell size presented as
mean and standard error. *P < 0.05, **P < 0.01, ***P < 0.001
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or without contact (Fig. 4c and d). The concentrations
varied between conditions; however, there was no condi-
tion which significantly altered TGFβ secretion.
Findings agree with previous data from horses,
humans, and dogs in which TGFβ is constitutively se-
creted and not, by definition, upregulated by activation
[14, 58, 59].
Activation of PBMCs results in the secretion of IFNγ,
TNFα, and IL-10; however, neither feline nor human
ASCs, even in the context of allogenic PBMCs, secreted
these mediators (Fig. 5). Typically, the inhibition of
lymphocyte proliferation is associated with decreased
IFNγ and TNFα production and variable IL-10 secretion.
Unlike human ASCs, feline ASCs only inhibited IFNγ
secretion in the absence of direct MSC-T cell contact
whereas, when ASCs were in contact with T cells, IFNγ
was not inhibited. Conversely, human ASCs were cap-
able of inhibiting IFNγ secretion when ASCs and T cells
were in direct contact; however, in the absence of con-
tact, ASCs were not able to inhibit IFNγ (Fig. 5a and b).
Both feline and human ASCs inhibited TNFα secretion;
however, feline ASCs were more able to inhibit TNFα,
like IFNγ, when ASCs were not in direct contact with T
cells (Fig. 5c and d). Activated feline ASCs did increase
PBMC secretion of IL-10; however, activated human
ASCs did not alter IL-10 secretion regardless of cell-cell
contact (Fig. 5e and f).
Transcriptome analysis of feline ASCs demonstrates their
relatedness and insight into their biological properties
Having defined and compared the biological features of
feline ASCs, transcriptome analysis was next performed
in order to evaluate the relatedness of the feline ASCs to
each other, as well as to human ASCs, and to gain
insight into the functional implications of the ASC gene
expression profile (full dataset in Additional file 2: Figure
S2; available at NCBI GEO Datasets Accession number:
GSE94773. Pair-wise correlation analyses of the gene-
level expression data (i.e., FPKM) for each ASC culture
demonstrated that there was a high level of similarity be-
tween the ASC preparations isolated from the three cats
(Pearson r = 0.853, 0.891, and 0.974) (Fig. 6a). There was
a significant overlap of genes (2743 genes, 89.00–
90.47%) that exhibited at least a moderate level of ex-
pression (i.e., ≥15 FPKM) in each ASC preparation. Sig-
nificant overlap of gene expression profiles from the
three feline ASC lines was highly expressed in 401 genes
(≥100 FPKM; Fig. 6b). In order to gain insight into the
functional significance of the ASC expression repertoire,
functional annotation analysis was performed on the
Fig. 2 Human and feline adipose-derived mesenchymal stem cells (ASCs) display similar proliferative capacity and immune-suppressive functions.
Doubling times were calculated for feline ASCs at passages 2–6 and for human ASCs at passages 3–6. The proliferation rate of human and feline
ASCs is comparable throughout multiple passages (a). Feline ASCs co-incubated with stimulated peripheral blood mononuclear cells (PBMCs) suppress
lymphocyte proliferation regardless of direct contact (transwells) (b). Human ASCs similarly inhibit leucoagglutinin (PHA)-induced lymphocyte
proliferation; however, direct contact with stimulated PBMCs leads to stronger inhibition than the transwell condition (c). Data presented as
mean and standard error. *P < 0.05, **P < 0.01, ***P < 0.001. BrdU 5-bromo-29-deoxyuridine, ConA concanavalin A, MSC mesenchymal stem cell
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most highly expressed genes (i.e., ≥100 FPKM; 401
genes) that were common to all ASCs, with the notion
that this would highlight the most prominent processes.
For this, the gene set was analyzed with tools available
from DAVID Bioinformatics Resources 6.7 that evaluate
gene-gene functional relationships and enrichment for
biological “modules” [49, 50]. There was over-
representation of gene ontology categories involved in a
number of processes, including: 1) the regulation of
apoptosis; 2) cell adhesion; 3) response to oxidative
stress; 4) regulation of cell differentiation; and 5) various
metabolic processes, including phosphate metabolism,
sterol metabolism, and oxidative phosphorylation
(Fig. 6c).
Finally, the potential similarity of feline ASCs to their
human counterparts was investigated by performing
meta-analysis with an RNA-Seq dataset from human
ASCs that were either undifferentiated (noninduced) or
induced to differentiate along the adipogenic, osteogenic,
and chondrogenic lineages (NCBI GEO Accession
GSE37521; Fig. 7) [51]. Genes exhibiting variance across
the human ASC cell types (≥2-fold change relative to
Fig. 3 Human and feline ASCs produce immunomodulatory mediators. Feline ASCs in the presence of proliferating peripheral blood mononuclear
cells (PBMCs) increase indoleamine 2,3 dioxygenase (IDO) activity (a). Increased IDO activity was observed by stimulated human ASCs, but was not
statistically significant (b). Production of prostaglandin E2 (PGE2) occurred in both standard and transwell conditions in cats; however, greater
production occurred when feline ASCs were in direct contact with stimulated PBMCs (c). Human ASCs produce PGE2 to the same magnitude with or
without contact to stimulated PBMCs (d). Interleukin-6 (IL-6) was significantly upregulated regardless of contact for both feline (e) and human (f) ASC
co-cultures. Feline ASCS produced vascular endothelial growth factor (VEGF) in standard and transwell conditions in cats (g). However, VEGF was not
significantly increased above baseline by stimulated human ASCs (h). Data presented as mean and standard error. *P < 0.05, **P < 0.01, ***P < 0.001.
ConA concanavalin A, MSC mesenchymal stem cell, PHA leucoagglutinin
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undifferentiated ASCs) were determined and then used as
the basis for hierarchical clustering with the feline ASCs.
The feline ASCs clustered closely and were intermingled
with the undifferentiated human ASCs, demonstrating
their similar patterns of gene expression to the human
ASCs, and providing additional evidence that the feline
ASCs are representative of undifferentiated phenotype
(Fig. 7). The variable gene expression patterns for the
human and feline ASCs was highlighted by the fact that
some human and feline ASC were clustered closer
together than human to human or feline to feline ASCs.
In addition, one undifferentiated human ASC line (hu-2)
and one feline uninduced ASC line (fel-2) were more
closely related to adipo-induced hASCs than to nonin-
duced human and feline ASCs (Fig. 7).
Discussion
Clinical trials with cell therapies are increasingly taking
advantage of companion animals with naturally occur-
ring diseases as relevant, surrogate models to support
novel human investigational drug applications (IND)
and veterinary investigational new animal drug applica-
tions (INAD) [19, 20, 30, 60]. Cats are a particularly im-
portant translational model for a number of diseases
that are similar in cats and humans, including FIV
(HIV) [61], T cell-mediated oral mucosa inflammation
[24], chronic renal failure [29], asthma [25], chronic en-
teropathy [26], and osteoarthritis. The goal of this work
was to profile feline ASCs and directly compare their
phenotypic, cellular, and immunomodulatory profiles
with human ASCs to deepen our understanding of
MSC-based therapies as we move towards mechanism-
of-action studies in animals and people. We found that
feline ASCs, like human ASCs, can be defined as MSCs
based on defined criteria (surface phenotype, differenti-
ation potential, morphology, doubling time, normal
karyotype) and that their transcriptome clusters closely
with uninduced (undifferentiated) human ASCs. Feline
ASCs inhibit mitogen-activated T-cell proliferation and
their profile of secreted immunomodulatory mediators
closely mimics that of human ASCs, dominated by
IDO, PGE2, TGFβ, IL-6, and IL-8. Feline ASCs are
highly activated and functional in the presence of the
proinflammatory cytokines, IFNγ and TNFα, and, like
human [6] and canine ASCs [12], their regulation of
IFNγ is complex and likely dictated by at least two
mechanisms, depending on whether or not the ASCs
are in direct contact with activated PBMCs.
The data we generated from human ASCs largely
mimicked data from studies that either compared
human ASCs with MSCs from other sources, especially
bone marrow, or studies that determined the immuno-
modulatory phenotype of human ASCs. Similar to others,
we found that ASCs were able to inhibit activated T-cell
proliferation with or without direct ASC-T cell contact
[62, 63]; however, we also found that this inhibition was
Fig. 4 Human and feline ASCs increase interleukin-8 (IL-8) but not transforming growth factor beta (TGFβ) above baseline peripheral blood
mononuclear cell (PBMC) production. Production of IL-8 by feline ASCs is significantly increased regardless of contact with stimulated PMBCs
(a). IL-8 is also produced by stimulated human ASCs with (P = 0.08) and without contact (b). Production of TGFβ by activated mesenchymal
stem cells (MSCs) is not altered from baseline expression regardless of contact in both cats (c) and humans (d). Data presented as mean and
standard error. *P < 0.05, **P < 0.01, ***P < 0.001. ConA concanavalin A, PHA leucoagglutinin
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more marked when ASCs were in contact with activated
cells. MSC-immune cell contact, especially in the context
of both IFNγ and TNFα, has been shown to upregulate
PD-1, VCAM-1, and ICAM-1 and this contact can then
augment the production of soluble mediators, notably
IDO [7, 21, 64]. Our data are also aligned with data from
fetal membrane, or decidual, MSCs that also inhibit
lymphocyte proliferation more profoundly in the presence
of MSC-immune cell contact [64, 65]. Contact-dependent
inhibition of immune cell function is thought to be more
important for local immunosuppression [65]. In the ab-
sence of cell-cell contact, human ASCs were unable to in-
hibit IFNγ secretion and IL-8 production was decreased.
Unlike human and other veterinary species studied to
date [11, 35], feline ASCs expanded in standard culture
conditions do not proliferate robustly in vitro after
passage 5 or 6 [31, 54]. This is in spite of the fact that,
similar to horses [35] and humans [66], adipose tissue is
still the tissue of choice for feline MSC therapy due to
the ease of collection, tissue abundance, and faster
growth kinetics [53]. The most likely consideration for
this poor, late-passage proliferation is inadequate cell
culture condition optimization. This phenomenon is inde-
pendent of feline foamy virus (FFV) infection as it occurs
in ASC lines from SPF cats as well as client-owned cats
free of FFV infection [31]. Our group has not investigated
cell culture optimization with media supplementation of
growth factors, increased FBS concentration, or cytokine
supplementation; however, optimization would likely
improve growth kinetics. Creating working cell banks of
autologous or allogeneic ASCs at passage 1 and expanding
to doses of 5 × 106 cells/kg (passages 2 or 3) for clinical
Fig. 5 Regulation of inflammatory mediators by human and feline ASCs differs. Feline ASCs in the presence of proliferating lymphocytes do not
inhibit production of interferon gamma (IFNγ). Removal of direct contact between ASCs and stimulated peripheral blood mononuclear cells
(PBMCs) led to a significant reduction in IFNγ production (a). Human ASCs in contact with PBMCs stimulated with leucoagglutinin (PHA) inhibit
production of IFNγ. However, when contact with activated PBMCs is removed, inhibition of IFNγ does not occur (b). Feline ASCs inhibit production of
tumor necrosis factor alpha (TNFα) with or without contact, with the transwell condition inhibiting production of the mediator to a greater extent (c).
Human ASCs inhibit production of TNFα regardless of contact with proliferating lymphocytes (d). Production of interleukin-10 (IL-10) in feline ASC
lymphocyte co-cultures increased significantly without contact and was also increased with contact (P = 0.06) (e). No alterations in IL-10 production
were observed by activated human ASCs (f). Data presented as mean and standard error. *P < 0.05, **P < 0.01, ***P < 0.001. ConA concanavalin A, MSC
mesenchymal stem cell
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Fig. 6 (See legend on next page.)
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use is readily achieved given the high number of ASCs ob-
tained from small feline fat samples even without culture
optimization.
MSCs derived from different tissues can vary substan-
tially in size; for example, equine cord blood-derived
MSCs are much larger than equine ASCs [67]. In this
study, we found that ASCs in humans and cats differ in
size, with feline ASCs being much smaller than human
ASCs. Cell size differences are likely to be irrelevant for
basic biological functions; however, recognizing cell size
differences may inform species-specific tissue engineering
protocols and scaffold features [68]. MSC size has also
been implicated in determining pulmonary entrapment
after intravascular cell administration [69].
The key mediators secreted by human and feline ASCs
were similar. We did not attempt to compare absolute
(See figure on previous page.)
Fig. 6 Transcriptome analysis reveals similarities between human and feline adipose-derived mesenchymal stem cells (ASCs) at the molecular level.
Total RNA was isolated from undifferentiated feline ASC primary cultures established from three different cats. Correlation coefficients (Pearson r) show
the relatedness of the different feline ASC cultures as determined by pair-wise correlation analysis of the gene-level FPKM data (a). Substantial similarity
of the feline ASC lines is demonstrated by the Venn diagram, which depicts a greater than ≥87% overlap in gene expression profiles (401 genes) based
on all genes exhibiting a high level of expression (≥100 FPKM) (b). Functional analysis reveals prominent biological processes in feline MSCs. Gene
annotation-enrichment analysis of the most highly expressed genes (≥100 FPKM) in common to the three ASC preparations was performed. The gene
ontology and pathway annotations (biological processes and pathways) specifically enriched within this gene list were filtered for statistical significance
(Fisher Exact P value ≤0.1), and selected, representative categories presented (c)
Fig. 7 Noninduced feline and human adipose-derived mesenchymal stem cells (ASCs) have similar gene expression profiles. Meta-analysis of feline
ASC RNA-Seq data was performed with a dataset for human ASCs (NCBI GEO Accession GSE37521). Comparison analyses were performed to identify
expression profiles distinctive for undifferentiated (noninduced) and differentiated ASCs. Induced and uninduced cell lines are separated as indicated
by a vertical line. Clustering of the differentially expressed genes was performed and the results depicted in the heatmap for the three feline ASC and
human ASC cultures. Each sample column represents averaged values of replicates
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concentrations of secreted mediators as the mitogens se-
lected (ConA and PHA) were different, the ELISA kits
were different, and the degree of stimulation varied in the
assays. Both PHA and ConA are nonspecific, potent T-cell
mitogens. Mitogen selection and concentration was based
on our early data examining proliferation kinetics and
degree of activation as well as other published data in cats
and humans [36–40]. Regardless, a few patterns are of
interest. TGFβ1, VEGF and, to a lesser extent, PGE2 were
the only mediators secreted to a measurable level by feline
and human ASCs at baseline with no activation. The con-
stitutive secretion of TGFβ1 concurs with previous findings
in human [6, 7], equine [14], and canine [12] ASCs. TGFβ1
is involved in immune regulation by and differentiation of
Foxp3+ regulatory T cells and Th17 cells, and may play an
important part in MSC immunomodulation although it is
not involved in the inhibition of lymphocyte proliferation
[7, 12, 70]. Interestingly, VEGF secretion was not increased
after mitogen stimulation in human ASCs; however, VEGF
secretion did increase after feline ASC activation. It may be
that VEGF secretion in human ASCs is more sensitive to
hypoxic signals rather than T-cell mitogens [71].
There were a number of differences in how feline and
human ASCs inhibited lymphocyte proliferation and in
their secretion profiles, with and without PBMC contact.
These data suggest that there are multiple different
mechanisms by which human and feline ASCs regulate
inflammatory (most notably IFNγ) and regulatory (IL-10)
mediator secretion by activated PBMCs, one dependent
on cell contact and one primarily mediated by soluble
factors. Also, PGE2 secretion was markedly diminished
in the absence of direct cell-cell contact for cats. Data
from our in vivo studies suggest that induction of T
regulatory cells may be important as a mechanism by
which MSCs cure oral inflammatory disease in cats
[24]. T regulatory cells classically require cell-cell con-
tact to function; however, many soluble mediators, in-
cluding PGE2, TGFβ1, and IL-10, can also play a role in
the induction of regulatory T cells [72, 73]. Deciphering
these mechanisms is critical as, although both cell-cell
contact and soluble mediator production are likely im-
portant in vivo, there is at least one condition under
which IFNγ secretion is not decreased. Sustained secre-
tion of IFNγ may have important implications for par-
ticular clinical applications as IFNγ stimulates MSCs,
derived from a number of tissues, to produce IDO,
TGFβ, and HGF, to increase cell-cell signaling via the
upregulation of PD-L1 and ICAM-1, and to generate
regulatory CD8+ T cells [21, 62, 64, 65, 74–76]. These
data are in agreement with data from our in vivo study
where two cats with severe, chronic, oral inflammation
that fully responded to ASC therapy (complete, sus-
tained disease resolution) did so in the context of high
serum concentrations of IFNγ [24].
Our findings suggest that uninduced feline ASCs are
highly similar to human ASCs in their basic morph-
ology, phenotype, and transcriptome. The goal of the
transcriptome analysis was to determine the similarity
of feline ASCs to human ASCs at the molecular level.
As such, we focused the analysis on the expression of
those genes that are highly relevant to MSC biology and
did not compare the relatedness of culture-expanded
feline ASCs to somatic feline tissues. It is likely that a
number of feline ASC-expressed genes are shared across
different feline tissues. Inclusion of biological controls
(feline somatic tissues) would be needed to fully determine
the stem-cell specificity of these data. Interestingly, the
RNA-Seq data from one human ASC line, induced to-
wards adipogenesis, was more closely aligned to one hu-
man and one feline ASC line that were uninduced. The
origin of our MSCs from adipose tissue may recapitulate
ASCs induced to differentiate along the adipose lineage
more closely than those induced to differentiate towards
bone or cartilage.
In summary, the activation of feline ASCs potentiates
the secretion of a panel of immunomodulatory media-
tors that is comparable to human ASCs and human fetal
decidual stem cells with one end result of decreasing
lymphocyte proliferation. These data provide additional
rationale for the use of naturally occurring diseases in
cats as appropriate surrogate models for human regen-
erative medicine trials with MSCs when the diseases are
also shown to be comparable. These data also provide
the first published immunomodulatory (secretion) and
transcriptome profile of feline ASCs from which further
mechanism-of-action studies can result.
Conclusion
These data provide the first comprehensive side-by-side
evaluation of human and feline ASCs including phenotype,
immunomodulatory profile, and transcriptome. Findings
suggest that feline ASCs are multipotent mesenchymal
stem cells that, when activated by IFNγ, modulate lympho-
cyte proliferation using soluble mediators that mirror the
human ASC secretion pattern. Transcriptome analysis re-
vealed similar gene expression profiles to uninduced human
ASCs and set the stage for deeper investigations using cats
as surrogate models for human cell therapy-based clinical
trials.
Additional files
Additional file 1: Figure S1. Representative karyotypes of feline and
human ASCs. Both feline (A, B) and human (C, D) ASCs have a normal
karyotype. (TIFF 19104 kb)
Additional file 2: Figure S2. Transcriptome analysis of ASCs. Full
dataset of ASC gene expression profile. RNA-Seq analysis was performed
on total mRNA prepared from three separate feline noninduced ASC
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